MN-KINDEVA-DRUG-DELIVERY
Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, today welcomes Jennifer Riter as Vice President of Analytical Services to head up the recently announced analytical services global business unit.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240318401921/en/
Jennifer Riter joins Kindeva Drug Delivery as Vice President of Analytical Services to lead new analytical services business unit. (Photo: Business Wire)
Riter comes to Kindeva from West Pharmaceutical where she spent the past 27 years in various technical and leadership roles, most recently serving as the Senior Director, Business and Technical Operations. She brings specific leadership and expertise in analytical testing which includes extractables and leachables, container closure integrity and device/combination product performance, and particle analysis. She is the current Chair of the Board of Directors for the Lock Haven University Foundation and teaches a class at University of Maryland Baltimore County as part of the combination products curriculum.
“Kindeva’s expertise in all areas of drug delivery and manufacturing is unmatched in the industry,” Riter said. “I am looking forward to working with the team on expanding our capabilities and expertise in analytical services and working with customers on their analytical approach and strategy for their combination products.”
“Jennifer’s experience blends knowledge of primary packaging components and containment and delivery systems with hands-on experience of providing technical support and analytical solutions to multinational customers,” said Kindeva Global Chief Commercial Officer David Stevens. “The long list of experience and technical knowledge she brings to the team enhances Kindeva as a global drug-device combination CDMO as well as builds the future of integrated and stand-alone analytical support for the wider pharmaceutical, biopharmaceutical, and medical device sector.”
Riter will be participating in and available to meet at industry conferences this spring, including two she is presenting at on behalf of Kindeva — the 2024 INTERPHEX Conference on April 17 in New York City and the Pharma Ed Combination Products Summit on May 3 in Philadelphia.
About Kindeva Drug Delivery
Kindeva Drug Delivery is a global contract development and manufacturing organization focused on drug-device combination products. We develop and manufacture products across a broad range of drug-delivery formats, including pulmonary & nasal, injectable, and transdermal. Our service offerings span early-stage feasibility through commercial scale drug product fill-finish, container closure system manufacturing, and drug-device product assembly. Kindeva serves a global client base from our state-of-the-art manufacturing, research, and development facilities located across the U.S. and U.K.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240318401921/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Completes STAR Market IPO, Becoming the First “H+A” Global Drug Innovator10.12.2025 03:50:00 CET | Press release
Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd. (“Biocytogen,” SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, today announced its successful listing on the Shanghai Stock Exchange STAR Market. This follows the Company’s listing on the Hong Kong Stock Exchange in September 2022 and marks a significant milestone in establishing Biocytogen as the first “H+A” dual-listed global drug innovator, reinforcing its mission to become the global headstream of new drugs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209977992/en/ The Company’s IPO price was set at 26.68 RMB per share, with an opening price of 58 RMB, representing a 117% increase over the offering price. Based on the opening price, Biocytogen’s market capitalization exceeds 25.9 billion RMB. Biocytogen’s proprietary RenMice® platforms (RenMab™, RenLite®, RenNano®, RenTCR-mimic™) enable the discovery of fully hum
Argo Infrastructure Partners Increases Ownership and Capital Commitment to TierPoint9.12.2025 23:00:00 CET | Press release
The latest investment brings total capital formation under Argo ownership to $3 billionDemonstrates a growing commitment to TierPoint from existing and new capital partners of Argo supporting the continued growth of its leading data center platform Argo Infrastructure Partners, LP (“Argo”), an established mid-market asset manager of essential infrastructure assets in North America, today announced it has acquired on behalf of its managed funds the equity interests of the majority of minority shareholders in TierPoint. The transaction reflects Argo’s continued conviction in TierPoint’s strategy and growth potential during a period of accelerating demand for TierPoint’s enterprise-class data center services. Since Argo’s initial investment in 2020, $3 billion of capital has been raised to fund growth and reduce TierPoint’s cost of capital by terming out debt facilities. The investment capital has advanced TierPoint’s market position as a data center services provider to enterprises, gove
Venture Global Announces Closing of $3,000,000,000 Senior Secured Notes by Venture Global Plaquemines LNG, LLC9.12.2025 22:30:00 CET | Press release
Venture Global, Inc. (“Venture Global”, NYSE: VG) announced today that its subsidiary, Venture Global Plaquemines LNG, LLC (“VGPL”) has closed an offering of $3,000,000,000 aggregate principal amount of senior secured notes, which has been issued in two series: (i) a series of 6.125% senior secured notes due 2030 in an aggregate principal amount of $1,750,000,000 (the “2030 Notes”) and (ii) a series of 6.500% senior secured notes due 2034 in an aggregate principal amount of $1,250,000,000 (the “2034 Notes” and, together with the 2030 Notes, the “Notes”). The 2030 Notes will mature on December 15, 2030, and the 2034 Notes will mature on June 15, 2034. Venture Global had previously announced the issuance of $2,500,000,000 of senior secured notes by VGPL on April 21, 2025, and $4,000,000,000 of senior secured notes by VGPL on July 3, 2025 (collectively, the “Existing Notes”), bringing the combined aggregate amount of senior secured notes issued by VGPL to $9,500,000,000 since the project
Doha Debates Hosts “In The Room: The Negotiators Podcast” Live at Doha Forum9.12.2025 18:09:00 CET | Press release
As the podcast enters its fifth season, global diplomacy and high-stakes negotiation take center stage. Qatar Foundation’s Doha Debates spotlighted the practice of high-stakes negotiation with a special live episode of its award-winning podcast with Foreign Policy, The Negotiators, at Doha Forum, following the launch of the podcast series’ fifth season on December 1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209171106/en/ Doha Debates spotlighted the practice of high-stakes negotiation with a special live episode of its award-winning podcast with Foreign Policy, The Negotiators, at Doha Forum, following the launch of the podcast series’ fifth season on December 1. (Photo: AETOSWire) Held in collaboration with The Negotiators’ special partner for this season, the International Peace Institute (IPI), and Doha Debates’ longstanding production partner, Foreign Policy, the episode featured a compelling conversation betwee
CoMotion GLOBAL 2025 Concludes in Riyadh with Landmark Deals and Global Mobility Breakthroughs9.12.2025 18:07:00 CET | Press release
Three-day summit unveils major AI research, city-led climate initiatives, and transformative partnerships in autonomous and electric air mobility, cementing Saudi Arabia’s role as a global hub for next-generation transport CoMotion GLOBAL 2025 concluded today after three transformative days that brought together global decision-makers, industry leaders, city executives, innovators, and investors to chart the future of mobility in Saudi Arabia and worldwide. Hosted for the first time in the King Abdullah Financial District (KAFD), Riyadh, the event showcased the Kingdom’s accelerating role as a global hub for next-generation transportation, sustainability leadership, and urban innovation. With more than 100 sessions spanning three days, CoMotion GLOBAL showcased forward-looking mobility strategies, multimodal transport breakthroughs, urban digital transformation, AI applications, and the dramatic rethinking of the movement of people and goods across global cities. Key moments from the e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom